HerAnova Lifesciences, 2 Burlington Woods Drive Suite 100, Burlington, MA (2026)

04/20/2026

In recognition of , we’re joining the conversation to raise awareness, foster understanding, and support those navigating the fertility journey.

This week and beyond, we stand with RESOLVE: The National Infertility Association, American Society for Reproductive Medicine and the infertility community in advancing awareness, improving access to care, and supporting more informed reproductive health journeys.

One of the most challenging aspects of infertility is uncertainty; many individuals spend years without clear answers or direction. Earlier insight can help guide more informed conversations and personalized care decisions.

At HerAnova, we are committed to advancing non-invasive diagnostic innovation for endometriosis and infertility in women’s health.

Learn more about National Infertility Awareness Week here: https://www.infertilityawareness.org/

04/16/2026

For patients navigating both infertility and chronic pain, uncertainty can be one of the most difficult parts. Having clearer insight earlier can help physicians anticipate risk, guide treatment planning, and better support patients through each stage of care.

New research published in Human Reproduction Open highlights an important and often underrecognized aspect of care for women with undergoing IVF.

In an international study of 546 patients, nearly half reported worsening pelvic pain following IVF, with similar patterns seen for dysmenorrhea and dyspareunia. For many, this is not just a statistic, but a meaningful impact on daily life during an already physically and emotionally demanding process. Patients who experienced pain flares immediately after a cycle were significantly more likely to report ongoing or worsening symptoms over time.

Read the full study here: https://bit.ly/41BsZ2s

At HerAnova Lifesciences, we are focused on helping bring that clarity forward. HerResolve™, our non-invasive, multi-omic blood test, is designed to detect endometriosis earlier, before or at the start of fertility care, enabling more informed, proactive decisions. By identifying the presence of disease sooner, clinicians can better assess potential contributors to pain, consider appropriate interventions, and tailor IVF strategies with greater confidence.

Learn more at HerAnova.com

04/14/2026

Persistent pelvic pain. Ongoing fertility challenges. No clear answers.

In one clinical scenario, a patient in her early 30s presented with symptoms including pelvic pain, fertility challenges and ongoing uncertainty.

Her provider incorporated HerResolve™, a blood-based test designed to detect markers associated with endometriosis, as part of her assessment.

The additional biological insight supported a more focused clinical discussion around potential next steps.

Situations like this highlight the role of earlier, data-informed evaluation in supporting clinical decision-making across women’s reproductive journeys.

Learn more: heranova.com

03/30/2026

March has been a meaningful and productive month for HerAnova.

Throughout 🎗️, we were proud to help lead conversations around earlier detection, informed fertility planning, and the importance of bringing greater clarity to care.

This month, our team engaged with leaders across reproductive medicine, minimally invasive surgery, and women’s health innovation at national meetings and industry forums. These discussions reinforced the critical role that clinically validated, biology-informed diagnostics play in advancing infertility and endometriosis evaluation. We were honored to contribute to forward-looking dialogue shaping the future of women’s healthcare.

HerResolve™, our non-invasive, blood-based test designed to detect endometriosis, continues to be integrated into fertility practice — equipping clinicians with objective molecular insight and supporting more confident, personalized treatment planning.

As March comes to a close, we remain focused on advancing meaningful progress in women’s health. The standard of care is evolving, and HerAnova is proud to be at the forefront of that transformation.

Learn more about HerAnova and HerResolve at HerAnova.com

03/26/2026

Continuing our 🎗series, we are sharing perspectives from leaders in reproductive medicine on the value of earlier clarity in fertility care.

Uncertainty is often one of the most difficult parts of the fertility journey.
For many patients with fertility concerns, endometriosis may be a contributing factor — yet symptoms alone do not always tell the full story. Earlier clarity can meaningfully shape clinical conversations and treatment planning.

As Sasha Hakman,MD, FACOG, of HRC Fertility shares:

“When a patient comes in with fertility concerns, the hardest part is the uncertainty. HerResolve™ provides something our field has needed for a long time, a non-invasive blood test to clearly detect endometriosis, a common contributor to fertility challenges. Even with years of clinical experience, symptoms alone don’t always tell the full story. By running HerResolve™ early, I can counsel patients with objective data, set realistic expectations from the start, and build a personalized fertility plan together. That clarity strengthens trust and allows us to move forward with confidence.”

HerResolve™ is our blood-based test designed to detect endometriosis, supporting earlier identification when symptoms raise concern. By introducing objective molecular insight into fertility evaluation, clinicians can counsel with greater precision and partner with patients in building informed, personalized care plans.

Earlier clarity strengthens confidence — for both physician and patient.

03/25/2026

An energizing exchange of ideas and perspectives at the inaugural Women's Health Executive & Research Summit (HERS).

Dr. Farideh Bischoff, our Chief Medical Officer and Head of Diagnostics, joined an outstanding panel for “Redefining Women’s Health: Diagnostics, Data and Disruption.” The conversation highlighted how diagnostics are reshaping the landscape of women’s health, from cancer screening to period tracking and beyond, with data-driven insights guiding both innovation and policy.

A central theme throughout the discussion was the growing role of big data in fueling meaningful advancements across the field. Dr. Bischoff shared perspectives on how AI-powered approaches are accelerating progress in detection, enabling more precise, earlier insights that can change the trajectory of care.

During 🎗️, this dialogue feels especially timely. HerResolve, our multi-omic, non-invasive blood-based test, demonstrates how advances in diagnostics can provide patients with earlier clarity and equip physicians with meaningful, data-driven insights, helping enable a more informed and proactive approach to women’s health.

Thank you to the HERS Summit organizers for convening such a dynamic and impactful session, and to moderator Mara Aspinall for guiding the conversation. We also extend our appreciation to fellow panelists Sofiat Akinola, Steve Gardner, and Neha Kumar for their valuable perspectives.

03/24/2026

HerAnova is live at the Women's Health Executive & Research Summit (HERS) Summit in San Diego.

Dr. Farideh Bischoff, Chief Medical Officer and Head of Diagnostics at HerAnova, will participate in the featured panel discussion, “Redefining Women’s Health: Diagnostics, Data, and Disruption,” taking place Tuesday, March 24 at 2:45 PM. The session will bring together industry leaders to explore how clinically validated diagnostics, advanced data strategies, and innovative care models are reshaping the future of women’s healthcare.

If you’re attending the Summit, we look forward to connecting and engaging in conversations that are advancing meaningful progress in women’s health.

03/23/2026

Grateful to have been part of during 🎗️ and to the organizers for bringing together such a thoughtful and collaborative community in reproductive medicine.

Throughout the meeting, we had the opportunity to connect with clinicians, embryologists, and industry peers, and the conversations were both insightful and energizing. One message came through clearly: there is real anticipation for a non-invasive, blood-based way to detect . It is a need that continues to be felt across clinical practice.

We also heard how important earlier answers are, not just at the beginning of an IVF journey, but in shaping care decisions well beyond it. There is a growing understanding of endometriosis as a chronic, systemic condition, and with that comes a shift toward more comprehensive, biology-driven approaches to care.

At HerAnova, these conversations reinforce why we built HerResolve. Our multi-omic blood test is designed to give patients clearer answers sooner, while providing physicians with actionable insights they can use to guide care with greater confidence, all through a simple blood draw.

We are encouraged by the level of engagement and the shared commitment to improving how endometriosis is understood and managed. Thank you again to the Pacific Coast Reproductive Society PCRS organizers and to everyone who took the time to connect with us.

03/18/2026

Continuing our 🎗 series, we’re highlighting how clearer diagnostic insight is informing surgical decision-making in fertility planning.

In fertility journeys, women often face the critical question of when surgical intervention may meaningfully influence outcomes. HerResolve™, our non-invasive blood test, is designed to detect endometriosis to help guide personalized decision making.

As James D. Kondrup, MD, board-certified OB-GYN and minimally invasive gynecologic surgeon CNY Fertility Florida, shares:

“From a surgical perspective, the hardest question is not whether endometriosis exists, but whether operating at a given point in a patient’s fertility journey will meaningfully change outcomes. HerResolve™ helps us better assess risk and personalize care. We use it to support surgical planning and align closely with our REI colleagues on when surgery should be considered prior to proceeding with the IVF process.”

Surgical timing in fertility care requires careful coordination, clinical judgment, and patient-centered dialogue. By delivering meaningful insight through a simple blood draw, HerResolve helps support risk assessment, interdisciplinary collaboration, and more personalized decision-making at pivotal moments.

Throughout this awareness month, HerAnova remains committed to advancing evidence-based tools that bring clarity to both medical and surgical pathways in women’s health.

03/16/2026

HerAnova is heading to Las Vegas for the American & Global College of Endometriosis Specialists () 2026 Annual Meeting.

We look forward to connecting with colleagues dedicated to advancing surgical excellence and evidence-based care.

Visit HerAnova at Booth 4 to learn more about HerResolve™, our blood-based test designed to detect endometriosis and support earlier, biology-informed clinical decision-making.

We’re also proud to share that Dr. Farideh Bischoff will be presenting her poster, “Laboratory Validation of Noninvasive Blood Test to Predict Presence or Absence of Endometriosis: Histology vs Visual Laparoscopy as Ground Truth,” on March 19. The presentation will highlight laboratory validation data supporting molecular detection of endometriosis measured against surgical reference standards.

Visit HerAnova.com/news-and-events to read the full announcement

If you’re attending AGCES in Las Vegas, we hope you’ll join Dr. Bischoff’s session and stop by Booth 4 to connect with our team.

03/12/2026

HerAnova will be exhibiting at the PCRS 2026 Annual Meeting in Rancho Mirage, California, March 18–22.

We look forward to connecting with reproductive medicine clinicians and leaders who are advancing thoughtful, evidence-based fertility care.

Visit us at Booth #604 to learn more about HerResolve™, our blood-based test designed to detect and support earlier, biology-informed clinical decision-making within fertility practice.

If you’re attending the PCRS 2026 Annual Meeting, we hope you’ll stop by the booth to meet our team and explore how molecular insight can help inform fertility evaluation and care planning.

Read the full announcement here: HerAnova.com/news-and-events

03/11/2026

As we continue recognizing 🎗, we are highlighting how earlier, more informed detection is shaping real-time decision-making in fertility care.

Across leading fertility practices, physicians are incorporating HerResolve™, our non-invasive blood test designed to detect , to help guide personalized treatment planning when timing and clarity matter most.

As Carrie Wambach, MD, board-certified in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility at Reproductive Partners Medical Group, shares:

“In fertility care, timing matters. HerResolve™ helps us personalize fertility plans and move to the most effective treatment in a timely manner. That clarity is especially valuable when counseling patients who are already navigating an emotional and time-sensitive fertility journey, providing added confidence at critical decision points.”

Fertility care is both scientific and deeply personal. By delivering meaningful diagnostic insight through a simple blood draw, HerResolve helps reduce uncertainty and supports personalized, biology-informed conversations between physician and patient.

During Endometriosis Awareness Month and beyond, HerAnova remains committed to advancing evidence-based tools that elevate care and bring greater clarity to women’s health.

HerAnova Lifesciences

04/20/2026

04/16/2026

04/14/2026

03/30/2026

03/26/2026

03/25/2026

03/24/2026

03/23/2026

03/18/2026

03/16/2026

03/12/2026

03/11/2026

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category